Arbor Trust Wealth Advisors LLC Lowers Stock Holdings in Johnson & Johnson $JNJ

Arbor Trust Wealth Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,076 shares of the company’s stock after selling 354 shares during the quarter. Arbor Trust Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Greenup Street Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after acquiring an additional 60 shares in the last quarter. Ellis Investment Partners LLC grew its position in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after purchasing an additional 62 shares during the last quarter. Cypress Wealth Services LLC increased its stake in Johnson & Johnson by 0.9% during the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after purchasing an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN raised its holdings in Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after buying an additional 64 shares during the last quarter. Finally, Global Strategic Investment Solutions LLC lifted its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after buying an additional 65 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. HSBC boosted their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Finally, The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $186.50 on Friday. The company has a market cap of $449.34 billion, a price-to-earnings ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business’s 50-day moving average is $184.25 and its two-hundred day moving average is $168.70. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.